Literature DB >> 19952796

Burden of fibromyalgia and comparisons with osteoarthritis in the workforce.

Nathan Kleinman1, James Harnett, Arthur Melkonian, Wendy Lynch, Barbara Kaplan-Machlis, Stuart L Silverman.   

Abstract

OBJECTIVES: To calculate the fibromyalgia (FM) burden of illness (BOI) from the employer perspective and to compare annual prevalence, work output, absence, and health benefit costs of employees with FM versus osteoarthritis (OA).
METHODS: Retrospective regression model analysis comparing objective work output, total health benefit (health care, prescription drug, sick leave, disability, workers' compensation) costs, and absence days for FM, versus OA and NoFM cohorts, while controlling for differences in patient characteristics.
RESULTS: FM prevalence was 0.73%; OA 0.90%. Total health benefit costs for FM were $8452 versus $11,253 (P < 0.0001) for OA and $4013 (P < 0.0001) for NoFM, with BOI = $4439. Total absence days were 16.8 versus 19.8 (P < 0.0001) and 6.4 (P < 0.0001), respectively. FM had significantly lower annual work output than NoFM (19.5%, P = 0.003) but comparable with OA.
CONCLUSION: FM places a significant cost, absence, and productivity burden on employers.

Entities:  

Mesh:

Year:  2009        PMID: 19952796     DOI: 10.1097/JOM.0b013e3181bb808b

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  15 in total

1.  [Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009].

Authors:  U Marschall; B Arnold; W Häuser
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

2.  Cursing the darkness: reactions to fibromyalgia.

Authors:  Manfred Harth
Journal:  Pain Res Manag       Date:  2013 Mar-Apr       Impact factor: 3.037

3.  Health coverage and its relation to the prevalence and intensity of symptomatic knee osteoarthritis.

Authors:  Jacob Clearfield; Neil A Segal
Journal:  J Investig Med       Date:  2011-08       Impact factor: 2.895

4.  Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.

Authors:  Nicole M Marlow; Kit N Simpson; Ivana A Vaughn; Ara Jo; James S Zoller; Edward B Short
Journal:  Pain Pract       Date:  2017-05-28       Impact factor: 3.183

Review 5.  Diagnostic and Medication Treatment Disparities in African American Children with ADHD: a Literature Review.

Authors:  Amy Glasofer; Catherine Dingley
Journal:  J Racial Ethn Health Disparities       Date:  2021-09-14

Review 6.  Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.

Authors:  Feng Xie; Bruno Kovic; Xuejing Jin; Xiaoning He; Mengxiao Wang; Camila Silvestre
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

7.  Evaluating the health and economic impact of osteoarthritis pain in the workforce: results from the National Health and Wellness Survey.

Authors:  Marco dacosta Dibonaventura; Shaloo Gupta; Margaret McDonald; Alesia Sadosky
Journal:  BMC Musculoskelet Disord       Date:  2011-04-28       Impact factor: 2.362

8.  Impact of self-rated osteoarthritis severity in an employed population: cross-sectional analysis of data from the national health and wellness survey.

Authors:  Marco Dacosta Dibonaventura; Shaloo Gupta; Margaret McDonald; Alesia Sadosky; Dan Pettitt; Stuart Silverman
Journal:  Health Qual Life Outcomes       Date:  2012-03-15       Impact factor: 3.186

Review 9.  Fibromyalgia and disability adjudication: no simple solutions to a complex problem.

Authors:  Manfred Harth; Warren R Nielson
Journal:  Pain Res Manag       Date:  2014 Nov-Dec       Impact factor: 3.037

10.  Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.

Authors:  X Peng; P Sun; D Novick; J Andrews; S Sun
Journal:  J Pain Res       Date:  2014-01-09       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.